Novartis earnings edge higher on Cosentyx, Entresto

(Reuters) – Core operating income at Novartis edged 3% higher in the first quarter as sales growth from new drugs was partly offset by unfavourable currency effects. Quarterly core operating income rose to $4.08 billion, up from $3.96 billion a year ea…